



## Havn Life CEO to Present at Zooming With LD, a Leading Platform for Microcap Companies

*CEO Tim Moore will appear on Tuesday, March 24th at 8:00 AM PT/ 11:00 AM ET*

### **March 19, 2021**

**Vancouver, BC - Havn Life Sciences Inc. (CSE: [HAVN](#)) (OTC: [HAVLF](#)) (FSE: [5NP](#))** (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, announced today that it will be presenting virtually at the upcoming Zooming with LD event on Wednesday, March 24th 2020 at 8:00 AM PT/11:00 AM ET.

Tim Moore, Chief Executive Officer of Havn Life, will give a 1-hour presentation to this audience of investors and media. Afterwards, Moore will be available for 1:1 meetings with attendees, offering an exclusive opportunity to ask questions and discuss Havn Life's business with the CEO. Founded in 2006, LD Micro is a leading, independent resource for the microcap world, curating events like Zooming With LD to connect the investment community with business leaders in the microcap space.

WHO: Tim Moore, Havn Life Sciences CEO

WHEN: Wednesday, March 24th 2020 at 8:00 AM PT/11:00 AM ET

WHERE: Investors and other individuals may access the virtual presentation by registering here:

[https://us02web.zoom.us/webinar/register/WN\\_WwKAg8NzRPqULf2w-UZqog](https://us02web.zoom.us/webinar/register/WN_WwKAg8NzRPqULf2w-UZqog)

Chris Lahiji, Founder of LD Micro and host of Zooming With LD, noted "Psychedelic medicine has the potential to be a game-changer for millions of people around the world. At LD Micro, we are always eager to give a platform to unique, forward-thinking companies. Havn Life is bringing a truly new vision to biotech and natural healthcare products."

### **On Behalf of The Board of Directors**

Tim Moore  
Chief Executive Officer

### **About Havn Life Sciences Inc.**

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and



fungi, and the development of natural health care products from non-regulated compounds. Learn more at: [havnlife.com](http://havnlife.com) and follow us on [Facebook](#), [Twitter](#), [Instagram](#), and [Youtube](#)

**Contact:**

Investor Relations: [ir@havnlife.com](mailto:ir@havnlife.com) 604 687 7130

Media: [savi@emergence-creative.com](mailto:savi@emergence-creative.com) 647 896-8078

**Cautionary Note Regarding Forward-Looking Statements**

Certain statements contained in this news release, including statements which may contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates”, or similar expressions, and statements related to matters which are not historical facts, such as statements regarding the contemplated completion of the Acquisition, are forward-looking information within the meaning of applicable securities laws. Such forward-looking statements reflect management’s expectations and are based on certain factors and assumptions and involve known and unknown risks and uncertainties which may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by such forward-looking statements. These factors should be considered carefully, and readers should not place undue reliance on the Company’s forward-looking statements. The Company believes that the expectations reflected in the forward-looking statements contained in this news release are reasonable, but no assurance can be given that these expectations will prove to be correct, nor that the Acquisition will be completed as contemplated, or at all. The Company undertakes no obligation to release publicly any future revisions to forward-looking statements to reflect events or circumstances after the date of this news or to reflect the occurrence of unanticipated events, except as expressly required by law.

**The CSE has not reviewed, approved or disapproved the content of this press release**

